16/09/2025
🚀Exciting Medical News: Enteromix – Russia’s New Personalized Cancer Vaccine with 100% Efficacy in Clinical Trials
Enteromix is a personalized mRNA-based cancer vaccine developed in Russia, has demonstrated 100% efficacy and safety in recent clinical trials. This could signal a major breakthrough in how we prevent, treat, and manage aggressive types of cancer.
How Enteromix works:
It harnesses mRNA vaccine technology (similar in principle to COVID-19 vaccines) to train the immune system to recognize and eliminate cancer cells.
The treatment is personalized for each patient, meaning the vaccine is tailored to their own RNA profile to target their specific cancer.
What the trials showed:
Complete safety in repeated doses, with no serious side effects observed.
It was effective in shrinking tumors, halting growth, and in many cases completely destroying cancerous tissue.
Initial versions are being developed for colorectal cancer; versions for glioblastoma (brain cancer) and certain melanomas are also in progress.
What’s next:
The vaccine has cleared the clinical trial phase but is now pending regulatory approval from the Russian Ministry of Health before being made available to the public.
👉 The promise of Enteromix is exciting — it may revolutionize cancer treatment, offering less toxic, more targeted options with fewer side effects than traditional treatments like chemotherapy and radiation.
